GlassScriptPhysician profile
Edward Alan Nash
NPI 1962428656
$5,899.11
in general payments reported to CMS, 2019-2025
47 companies · $976 in 2025
The $976 reported for 2025 was more than what 87% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $508 · 2021: $919 · 2022: $917 · 2023: $973 · 2024: $835 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,717.41 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $473.41 | 2019-2025 | Belbuca, Xtampza, Nucynta |
| Pfizer INC. | $462.50 | 2023-2025 | |
| Eisai INC. | $243.96 | 2020-2021 | |
| Lilly USA, LLC | $215.95 | 2019-2024 | Emgality, Reyvow |
| Mdd US Operations, LLC | $174.84 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $172.00 | 2023-2025 | Xeomin |
| Lundbeck LLC | $168.85 | 2021-2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $162.14 | 2019-2024 | Ztlido |
| Horizon Therapeutics Plc | $150.73 | 2019-2022 | |
| Abbott Laboratories | $144.67 | 2021 | |
| Allergan, INC. | $128.10 | 2019-2021 | |
| Bausch Health US, LLC | $102.22 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $96.31 | 2022 | |
| Daiichi Sankyo INC. | $94.98 | 2019 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.